Skip to content
Clinical Development

[Webinar] Getting Ahead of the Expanding Landscape: Radiopharmaceutical Dosimetry

  • August 2, 2021
The demands for radiopharmaceutical dosimetry are growing rapidly. This need impacts design of clinical trials for a wide variety of oncologic diseases (e.g. neuroendocrine tumors (NETs), prostate cancer, lung, breast, and GI cancer) and is changing the way theragnostic trials are being conducted and designed. Biotech companies and nuclear medicine departments are focusing on dosimetric approaches that enhance therapeutic benefits to patients while adhering to regulatory authority requirements. Well informed dosimetry input is essential for achieving success in radiopharmaceutical therapy clinical trials.

In this webinar, Medpace experts explore the medical, operational, imaging, and regulatory considerations for radiopharmaceutical dosimetry. With a focus on solid tumors, we discuss the current landscape and how this may alter your approach to dosimetry and your overall program. We explore the challenges of conducting dosimetry in all phases of trials, offering insights into trial start-up, dosimetry conduct, collection, and implementation to seamlessly execute radiopharmaceutical therapy studies as part of your overall clinical development plan.

Learn more about Medpace’s specialized expertise and track record of success conducting radiopharmaceutical studies.